Johnson DB - Search Results

1

Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis.

Wang DY, Ye F, Zhao S, Johnson DB. Wang DY, et al. Among authors: johnson db. Oncoimmunology. 2017 Jul 5;6(10):e1344805. doi: 10.1080/2162402X.2017.1344805. eCollection 2017. Oncoimmunology. 2017. PMID: 29123955 Free PMC article.

2

Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.

Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner JP, Powers JG, Shinn L, Kelley MC, Joseph RW, Sosman JA. Johnson DB, et al. Cancer Immunol Res. 2013 Dec;1(6):373-7. doi: 10.1158/2326-6066.CIR-13-0092. Cancer Immunol Res. 2013. PMID: 24490176 Free PMC article.

3

BRAFV600E-mutant melanoma presenting with cardiac involvement.

Johnson DB, Sosman JA. Johnson DB, et al. J Natl Compr Canc Netw. 2014 May;12(5):611-5. doi: 10.6004/jnccn.2014.0065. J Natl Compr Canc Netw. 2014. PMID: 24812130 Free PMC article.

4

Immune checkpoint inhibitors in NSCLC.

Johnson DB, Rioth MJ, Horn L. Johnson DB, et al. Curr Treat Options Oncol. 2014 Dec;15(4):658-69. doi: 10.1007/s11864-014-0305-5. Curr Treat Options Oncol. 2014. PMID: 25096781 Free PMC article. Review.

5

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. Johnson DB, et al. J Clin Oncol. 2014 Nov 20;32(33):3697-704. doi: 10.1200/JCO.2014.57.3535. Epub 2014 Oct 6. J Clin Oncol. 2014. PMID: 25287827 Free PMC article. Clinical Trial.

6

Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.

Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM. Johnson DB, et al. Cancer Immunol Res. 2015 May;3(5):464-9. doi: 10.1158/2326-6066.CIR-14-0217. Epub 2015 Feb 3. Cancer Immunol Res. 2015. PMID: 25649350 Free PMC article. Clinical Trial.

7

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.

Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA. Johnson DB, et al. Cancer Immunol Res. 2015 Mar;3(3):288-295. doi: 10.1158/2326-6066.CIR-14-0207. Cancer Immunol Res. 2015. PMID: 25736262 Free PMC article.

8

Nivolumab in melanoma: latest evidence and clinical potential.

Johnson DB, Peng C, Sosman JA. Johnson DB, et al. Ther Adv Med Oncol. 2015 Mar;7(2):97-106. doi: 10.1177/1758834014567469. Ther Adv Med Oncol. 2015. PMID: 25755682 Free PMC article. Review.

9

Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review.

Johnson DB, Peng C, Abramson RG, Ye F, Zhao S, Wolchok JD, Sosman JA, Carvajal RD, Ariyan CE. Johnson DB, et al. Oncologist. 2015 Jun;20(6):648-52. doi: 10.1634/theoncologist.2014-0468. Epub 2015 May 11. Oncologist. 2015. PMID: 25964307 Free PMC article.

10

Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.

Johnson DB, Puzanov I, Kelley MC. Johnson DB, et al. Immunotherapy. 2015;7(6):611-9. doi: 10.2217/imt.15.35. Epub 2015 Jun 22. Immunotherapy. 2015. PMID: 26098919 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results